Released May 14, 2024, after the close
10-Q filed May 14, 2024, 44 days after period end · 0001390478-24-000010
Q1 2024 · 10-Q
Revenue—
Net Income-$9.57M-$9.57M N/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.21-$0.21 N/M vs Q1 2023no prior Q4 2023 on file
Operating Income-$9,645,000N/M
Operating Cash Flow-$10,761,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | — | $0.00 | $1.00M | $5.70M |
| Net Income | -$9.57M | -$11.10M | -$16.74M | -$2.40M |
| EPS Diluted | -$0.21 | -$0.47 | -$1.05 | -$0.16 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR